68Ga-PDT01: Preclinical PET Imaging Data for PD-L1 Expression

68Ga-PDT01, a novel peptide-based PET tracer, demonstrated a tumor-to-muscle ratio exceeding 6.00 at 1 hour post-injection in subcutaneous tumor models. Cong Wang developed this dataset, which includes binding affinity data (KD = 304 ± 26 nM) and results from cisplatin-induced PD-L1 upregulation experiments. The data, last updated in June 2026, supports noninvasive assessment of PD-L1 expression for diagnostic and therapeutic monitoring.

Use Cases

• Validate PD-L1 binding affinity of novel tracers based on the reported KD value of 304 ± 26 nM.
• Benchmark tumor visualization performance in preclinical models using the described tumor-to-muscle ratios.
• Study dynamic PD-L1 modulation by analyzing the ~3.16-fold uptake increase following cisplatin treatment.
• Guide the development of PD-L1-targeted diagnostic protocols based on the tracer's specific uptake and blocking behavior.

Strengths

• Includes specific quantitative binding affinity data (KD = 304 ± 26 nM).
• Reports clear tumor visualization metrics with tumor-to-muscle ratios >6.00.
• Demonstrates tracer sensitivity to dynamic PD-L1 modulation with a ~3.16-fold uptake increase.

Limitations

• Metadata completeness is limited; actual data quality and structure require manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred from the PDB file.
• The dataset is very small at 236.1 KB, indicating limited scope and likely a focused experimental dataset.

Provenance

Source

figshare

Collection Method

Preclinical laboratory research involving tracer development and in vivo PET imaging.

Freshness

Last updated 2026-06-01 05:33:20.